Literature DB >> 15739561

Multimodal metabolic imaging of cerebral gliomas: positron emission tomography with [18F]fluoroethyl-L-tyrosine and magnetic resonance spectroscopy.

Frank Willi Floeth1, Dirk Pauleit, Hans-Jörg Wittsack, Karl Josef Langen, Guido Reifenberger, Kurt Hamacher, Martina Messing-Jünger, Karl Zilles, Friedrich Weber, Walter Stummer, Hans-Jakob Steiger, Gabriele Woebker, Hans-Wilhelm Müller, Heinz Coenen, Michael Sabel.   

Abstract

OBJECT: The purpose of this study was to determine the predictive value of [18F]fluoroethyl-L-tyrosine (FET)-positron emission tomography (PET) and magnetic resonance (MR) spectroscopy for tumor diagnosis in patients with suspected gliomas.
METHODS: Both FET-PET and MR spectroscopy analyses were performed in 50 consecutive patients with newly diagnosed intracerebral lesions supposed to be diffuse gliomas on contrast-enhanced MR imaging. Lesion/brain ratios of FET uptake greater than 1.6 were considered positive, that is, indicative of tumor. Results of MR spectroscopy were considered positive when N-acetylaspartate (NAA) was decreased in conjunction with an absolute increase of choline (Cho) and an NAA/Cho ratio of 0.7 or less. An FET lesion/brain ratio, an NAA/Cho ratio, and signal abnormalities on MR images were compared with histological findings in neuronavigated biopsy specimens. The FET lesion/brain ratio and the NAA/Cho ratio were identified as significant independent predictors for the histological identification of tumor tissue. The accuracy in distinguishing neoplastic from nonneoplastic tissue could be increased from 68% with the use of MR imaging alone to 97% with MR imaging in conjunction with FET-PET and MR spectroscopy. Sensitivity and specificity for tumor detection were 100 and 81% for MR spectroscopy and 88 and 88% for FET-PET, respectively. Results of histological studies did not reveal tumor tissue in any of the lesions that were negative on FET-PET and MR spectroscopy. In contrast, a tumor diagnosis was made in 97% of the lesions that were positive with both methods.
CONCLUSIONS: In patients with intracerebral lesions supposed to be diffuse gliomas on MR imaging, FET-PET and MR spectroscopy analyses markedly improved the diagnostic efficacy of targeted biopsies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15739561     DOI: 10.3171/jns.2005.102.2.0318

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  42 in total

1.  MRI-suspected low-grade glioma: is there a need to perform dynamic FET PET?

Authors:  Nathalie L Jansen; Vera Graute; Lena Armbruster; Bogdana Suchorska; Juergen Lutz; Sabina Eigenbrod; Paul Cumming; Peter Bartenstein; Jörg-Christian Tonn; Friedrich Wilhelm Kreth; Christian la Fougère
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-04-11       Impact factor: 9.236

2.  Case 11: a young woman with ring-enhancing brain lesions.

Authors:  Irene Cortese; Avindra Nath
Journal:  MedGenMed       Date:  2006-01-05

Review 3.  Switching on the lights for real-time multimodality tumor neuroimaging: The integrated positron-emission tomography/MR imaging system.

Authors:  S Bisdas; T Nägele; H-P Schlemmer; A Boss; C D Claussen; B Pichler; U Ernemann
Journal:  AJNR Am J Neuroradiol       Date:  2009-11-26       Impact factor: 3.825

4.  18F-AFETP, 18F-FET, and 18F-FDG imaging of mouse DBT gliomas.

Authors:  Kiran Kumar Solingapuram Sai; Chaofeng Huang; Liya Yuan; Dong Zhou; David Piwnica-Worms; Joel R Garbow; John A Engelbach; Robert H Mach; Keith M Rich; Jonathan McConathy
Journal:  J Nucl Med       Date:  2013-05-06       Impact factor: 10.057

Review 5.  Differentiating tumor recurrence from treatment necrosis: a review of neuro-oncologic imaging strategies.

Authors:  Nishant Verma; Matthew C Cowperthwaite; Mark G Burnett; Mia K Markey
Journal:  Neuro Oncol       Date:  2013-01-16       Impact factor: 12.300

6.  Spatial Relationship of Glioma Volume Derived from 18F-FET PET and Volumetric MR Spectroscopy Imaging: A Hybrid PET/MRI Study.

Authors:  Jörg Mauler; Andrew A Maudsley; Karl-Josef Langen; Omid Nikoubashman; Gabriele Stoffels; Sulaiman Sheriff; Philipp Lohmann; Christian Filss; Norbert Galldiks; Elena Rota Kops; N Jon Shah
Journal:  J Nucl Med       Date:  2017-08-28       Impact factor: 10.057

7.  Uptake of 18F-fluorocholine, 18F-fluoro-ethyl-L: -tyrosine and 18F-fluoro-2-deoxyglucose in F98 gliomas in the rat.

Authors:  Nicolas Spaeth; Matthias T Wyss; Jens Pahnke; Gregoire Biollaz; Amelie Lutz; Kerstin Goepfert; Gerrit Westera; Valerie Treyer; Bruno Weber; Alfred Buck
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-03-15       Impact factor: 9.236

8.  Functional brain imaging: an evidence-based analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2006-12-01

Review 9.  Post-treatment imaging changes in primary brain tumors.

Authors:  Barbara J O'Brien; Rivka R Colen
Journal:  Curr Oncol Rep       Date:  2014       Impact factor: 5.075

10.  [18F]-fluoro-ethyl-L-tyrosine PET: a valuable diagnostic tool in neuro-oncology, but not all that glitters is glioma.

Authors:  Markus Hutterer; Martha Nowosielski; Daniel Putzer; Nathalie L Jansen; Marcel Seiz; Michael Schocke; Mark McCoy; Georg Göbel; Christian la Fougère; Irene J Virgolini; Eugen Trinka; Andreas H Jacobs; Günther Stockhammer
Journal:  Neuro Oncol       Date:  2013-01-17       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.